Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer

Published by: Decision Resources

Published: Apr. 9, 2009 - 33 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Oncology Markets

Therapeutic Cancer Antibodies

Antibodies Already on the Market

Antibodies in Late-Stage Development

Cancer Vaccines

Vaccine Technologies

Clinical Development Pipeline

Industry-Shaping Events

Combination MAb Therapies Not As Obvious As Hoped

Some Cancer Vaccine Companies on the Brink

Recent Deals and Business Strategies

Antibody-Based Dealmaking

Lilly’s Acquisition of ImClone Systems

Roche’s Hostile Takeover of Genentech

Merck & Co.’s Planned Merger with Schering-Plough

Cancer Vaccine Dealmaking

GlaxoSmithKline and Innogenetics

Pfi zer and Celldex Therapeutics

Merck Serono and Oncothyreon

Takeda and Cell Genesys

Oxford BioMedica and Sanofi -Aventis

Transgene and Roche

Market Drivers—MAb-Based Immunotherapies

Additional Indications

Shifts to Earlier-Stage Disease

Biomarkers

Biosimilars

Cost

Combination Targeted Therapies

Market Drivers—Cancer Vaccines

Outlook

Tables

1. Marketed Antibody Therapies for Oncology

2. Select Antibody Therapies in Phase II or Phase III Development for Oncology

3. Cancer Vaccines in Phase III Development or Later

4. Select Combination Targeted Therapies in Development, 2008

5. Dealmaking: Cancer Monoclonal Antibodies, 2007 and 2008

6. Dealmaking: Select Cancer Vaccines, 2008

7. Dealmaking: Biomarkers Driving the Development and Sale of Targeted Cancer Therapies, 2008

8. Potential Biosimilar Entry Dates for Marketed Monoclonal Antibody-Based Immunotherapies

9. Cost Comparison of Targeted Therapy Cancer Treatment in the Adjuvant and Advanced-Stage Settings

Figures

1. Forecasted Growth Rate for the Oncology Market, 2007-2014

2. Top Ten Companies in the Oncology Market, 2007 and 2014

3. Targeted Monoclonal Antibody Therapies: Combined Treatment in Metastatic Colorectal Cancer

4. Commercial Potential of Treating Early-Stage and Late-Stage Cancer

Abstract

Introduction

Targeted cancer therapies have achieved phenomenal growth, and many MAb-based immunotherapies are blockbusters or mega-blockbusters. This market success is due not only to these MAbs’ ability to treat unmet need in many cancers but also to the high cost of immunotherapies and biologics in general. Competition is increasing as more companies move into this arena; also, biosimilars will soon enter markets. Meanwhile, the cancer vaccine market is signifi cantly behind the MAb-based market in terms of products on the market, a robust pipeline, and workable technologies, but researchers hold out hope for the eventual success of this emerging market segment.

Get the Answers You Need to Shape Your Strategy
  • Eli Lilly’s CEO John Lechleiter told investors that oncology is going to be a sustainable play for many years to come. What is the outlook for the oncology market? Why are new companies fl ooding targeted therapy markets?
  • Companies are looking to gain a foothold in biologics markets or to extend MAb franchises. What types of therapeutic cancer MAb deals have taken place in the last two years? What strategies are companies using?
  • The emerging cancer vaccine market is signifi cantly behind the therapeutic cancer MAb market. What is the key issue involved in developing cancer vaccines? What technologies are in development? What deals are being made?
  • Bristol-Myers Squibb’s CEO James M. Cornelius told investors that an ImClone acquisition was the next logical step in the company’s almost ten-year relationship with ImClone. Why did BMS want to acquire ImClone? What key factor played in Lilly’s successful bid and acquisition of ImClone?
  • Roche has transitioned its pharmaceutical business with a focus on specialty segments and biologics. What was involved in Roche’s eight-month struggle to take over Genentech? Why was the winning bid agreeable to both parties?
  • Schering-Plough’s CEO Fred Hassan said stunning and accelerating changes in the global macro environment are driving changes in the pharma industry. Why did Schering-Plough accept Merck & Co.’s offer for a reverse merger? What technologies were key to the merger strategy?
Scope
  • Therapeutic monoclonal antibodies: Late-stage pipeline, targets, gold standards, combination MAb therapies, engineered/ optimized antibodies, next-generation antibodies, biosimilar market entry dates, patent expiry.
  • Cancer vaccines: Late-stage pipeline, marketed vaccines, vaccine technologies, troubled companies.
  • Biosimilars: Patent expiry, market entry dates, companies facing signifi cant challenges, big pharmaceutical companies moving into this market.
  • Dealmaking trends and opportunities: Antibody-based deals, three therapeutic MAb-related mergers and acquisitions involving Big Pharma, six cancer vaccine deals involving Big Pharma.
  • Market drivers: Indication expansion, cost, early-stage disease, biomarkers, biosimilars, combination therapies, evolving technologies, survey of oncologists and managed care organization pharmacy directors, formulary coverage of therapeutic cancer MAbs, Decision Resources’ Drug Comparator Model.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009